Xspray Pharma AB (publ) (LON:0GHZ)

Market Cap	114.84M
Revenue (ttm)	n/a
Net Income (ttm)	-20.05M
Shares Out	n/a
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162
Average Volume	912
Open	34.50
Previous Close	35.85
Day's Range	34.35 - 34.50
52-Week Range	30.85 - 77.70
Beta	0.82
RSI	44.96
Earnings Date	Aug 6, 2025

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 27
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GHZ

Financial Performance

Financial numbers in SEK